Clovis Oncology is advancing the fight against cancer. Founded in 2009, Clovis Oncology is a commercial-stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our pursuit is to improve the lives of people living with cancer. We believe our approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, we have the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis Oncology’s management team has extensive experience in the development of novel cancer therapies and a shared commitment to the company’s vision for meaningful improvements in the lives of patients with cancer. Clovis Oncology (NASDAQ: CLVS) is headquartered in Boulder, Colorado. Please visit our website for more information, including additional office locations in the U.S. and Europe.
Location: United States, Colorado, Boulder
Employees: 201-500
Total raised: $275M
Founded date: 2009
Investors 7
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
18.06.2013 | - | $275M | - | xconomy.co... |
Mentions in press and media 14
Date | Title | Description | Source |
04.10.2022 | Pfizer’s PARP inhibitor combo treatment passes primar... | Pfizer acquired both Xtandi and Talzenna, a PARP inhibitor, in its $14 billion buyout of Medi... | endpts.com... |
31.03.2022 | Clovis Stock Is Soaring. The Biotech’s Ovarian Cancer Drug L... | Shares of the small biotech firm Clovis Oncology jumped more than 40% on Thursday, after the company... | barrons.co... |
24.08.2021 | Clovis Oncology : Announces Availability of and Reimbursemen... | Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and r... | marketscre... |
19.03.2021 | Clovis Oncology’s Rubraca® (rucaparib) Significantly Improve... | BOULDER, Colo.--(BUSINESS WIRE)--Mar 19, 2021-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that... | oaoa.com/n... |
18.05.2020 | Clovis' Rubraca wins prostate cancer approval, but data... | While AstraZeneca and Merck’s market-leading Lynparza seemingly pipped Clovis Oncology’s ... | endpts.com... |
03.12.2018 | GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billio... | Tesaro’s only marketed product is Zejula (niraparib), a PARP inhibitor approved for the maintenance ... | medcitynew... |
25.03.2015 | This entrepreneur nearly lost his company. Here’s how litiga... | In 2009, Chant, who had previously founded G-Zero Therapeutics (now G-One Therapeutics), heard about... | medcitynew... |
20.11.2013 | Clovis Oncology Acquires Ethical Oncology Science for up to ... | Clovis Oncology (NASDAQ:CLVS), a Boulder, Colorado-based biopharmaceutical company focused on acquir... | finsmes.co... |
17.10.2013 | Clovis Oncology CEO Mahaffy Opens Up About Company’s Turbule... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Seeing your cornerstone product “f... | xconomy.co... |
18.06.2013 | Clovis Oncology Closes $275M Offering Following Two Pivotal ... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Clovis Oncology’s big two weeks ca... | xconomy.co... |
Show more